Antihypertensives: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
(3 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
===Antihypertensive types=== | |||
*[[Diuretics]] | *[[Diuretics]] | ||
*[[Calcium channel blockers]] | *[[Calcium channel blockers]] | ||
Line 12: | Line 13: | ||
==See Also== | ==See Also== | ||
*[[Hypertension (main)]] | *[[Hypertension (main)]] | ||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Cardiology]] |
Latest revision as of 20:07, 19 September 2019
Antihypertensive types
- Diuretics
- Calcium channel blockers
- ACE inhibitors
- Angiotensin II receptor antagonists (ARBs)
- Adrenergic receptor antagonists
- Alpha-2 agonists
Initial outpatient hypertension medications
- First line for people without comorbidities
- Hydrochlorothiazide 12.5mg, max 25mg
- Need labs before starting, does not work in people with CKD
- Hydrochlorothiazide 12.5mg, max 25mg
- First line for people with DM and/or proteinuria
- ACEi/ARB: Lisinopril either Qday or BID
- Need Chem 10 before and after starting to check for hyperkalemia and creatinine
- Start 10mg lisinopril QD
- ACEi/ARB: Lisinopril either Qday or BID
- Anyone with CAD, CHF
- Beta-Blocker (do not need labs)
- Amlodipine for anyone, except for people with LE edema (do not need labs)
- Start amlodipine 5mg QD
- Diltiazem for proteinuria in people unable to tolerate ACEi (do not need labs)
- Lasix for CHF and/or lower extremity edema secondary to proteinuria
JNC 8 Recommendations[1]
Population | Non-black Patients | Black Patients |
---|---|---|
General population | thiazide, CCB, ACEI, or ARB | thiazide or CCB |
CKD | ACEI or ARB | ACEI or ARB |
DM | thiazide, CCB, ACEI, or ARB | thiazide or CCB |
See Also
References
- ↑ James PA, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5):507-520.